<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04272931</url>
  </required_header>
  <id_info>
    <org_study_id>NL71535.068.19</org_study_id>
    <nct_id>NCT04272931</nct_id>
  </id_info>
  <brief_title>Dragon 1: Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE)</brief_title>
  <acronym>DRAGON</acronym>
  <official_title>DRAGON 1- Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization to Accelerate Future Liver Remnant (FLR) Hypertrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Koningin Wilhelmina Fonds</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Brief Summary: Some colorectal liver metastases can only be resected after inducing liver
      regeneration by portal vein embolization (PVE) to increase size function of the future liver
      remnant (FLR). While PVE is standard, embolization of portal vein and hepatic veins (PVE/HVE)
      on one side of the liver may faster and more extensive liver size and function growth.
      PVE/HVE is a novel procedure and requires a safety and feasibility evaluation in a pretrial
      (DRAGON1) to then be compared in a randomized controlled trial (RCT) to PVE (DRAGON 2).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed Description: Resection of liver metastases from colorectal cancer (CRLM) improves
      survival compared to chemotherapy alone and may lead to cure in up to 40% of patients.
      Surgical resectability is limited by location of metastases and by FLR size and function.
      Commonly, the volume of the future liver remnant (FLR) should be at least 30% of the
      functional FLR volume. If this volume criterion is not met, the induction of liver
      regeneration between a two-stage hepatectomy is performed at many centers, with the aim to
      render patients resectable and reduce the risk of post hepatectomy liver failure. Gold
      standard to induce regeneration is the embolization of the portal vein branches to the tumor
      carrying liver (PVE) to induce regeneration of the FLR. Recently, combined embolization of
      both portal and hepatic veins (PVE/HVE) has been described as an alternative to portal vein
      embolization because it accelerates and increases growth of the FLR. PVE/HVE combines
      simultaneous embolization of the portal main branches into the tumor bearing liver and the
      hepatic vein draining them. The tissue in the part of the liver treated with PVE/HVE stays
      viable because the hepatic artery continues to supplies the liver deprived of portal and
      hepatic veins. Preclinical studies in pigs have demonstrated feasibility of this method and
      human case series show accelerated and increased liver growth. No multi-center evaluation has
      been performed so far. DRAGON 1 is an international, prospective, multi-center trial to test
      enrolment capacity of participants and safety of portal and hepatic vein embolization
      (PVE/HVE). DRAGON 1 will form the basis of the RCT DRAGON 2 to compare PVE with PVE/HV.
      DRAGON 2 is expected to start in 2021.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 8, 2020</start_date>
  <completion_date type="Anticipated">May 7, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 7, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Multicenter, international, prospective, multi-center trial to test enrolment capacity of participants and safety of Portal and Hepatic Vein Embolization (PVE/HVE): DRAGON 1 will form the basis of a planned subsequent trial (&quot;DRAGON 2&quot;) that will compare PVE with PVE/HVE. In DRAGON 1 every center has to demonstrate the ability to enroll 3 patients in 12 months safely</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ability of each center to enroll 3 patients in 12 months without mortality due to the intervention.</measure>
    <time_frame>1 year/ 90 day mortality</time_frame>
    <description>Ability of each center to enroll 3 patients for PVE/HVE in 12 months safely and perform the procedure including the liver resection without 90-day mortality after resection due to complications. If this goal is achieved center will be enrolled in DRAGON 2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessment: standardized future liver remnant volume</measure>
    <time_frame>6 weeks</time_frame>
    <description>Increased of standardized future liver remnant volume between initial imaging and imaging at 1 week, 3 weeks, 6 weeks, degree of hypertrophy based on standard future liver remnant volume, kinetic growth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility assessment: resection rate</measure>
    <time_frame>1 year follow up</time_frame>
    <description>ion of patients proceeding to complete resection (=resection rate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality assessment</measure>
    <time_frame>90 days</time_frame>
    <description>90-mortality after resection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival after PVE/HVE</measure>
    <time_frame>1 year follow up</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oncological effectiveness of PVE/HVE</measure>
    <time_frame>1 year</time_frame>
    <description>Disease-free survival after 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General complication assessment</measure>
    <time_frame>90 days</time_frame>
    <description>90-day complications, general (Clavien-Dindo)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver specific complication assessment</measure>
    <time_frame>90 days</time_frame>
    <description>90-day complications, liver specific (FABIB-classification)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Colorectal Cancer Liver Metastases</condition>
  <arm_group>
    <arm_group_label>Portal and Hepatic Vein Embolization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 patients per center over one year approximately 90 patients in total. Patients will undergo portal vein and hepatic vein embolization instead of only portal vein embolization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Portal and Hepatic Vein Embolization</intervention_name>
    <description>Procedure/Surgery: Combined portal vein embolization and hepatic vein embolization (PVE/HVE) • All techniques of PVE allowed (ipsi-lateral, contra-lateral, trans-splenic, all embolization agents except for ethanol alone) • All modifications of HVE allowed (venous occlusion umbrellas; trans-jugular, trans-hepatic, no use of vein glue to avoid lung embolization; staged approach allowed, but first PVE, then HVE and within 48 hours)</description>
    <arm_group_label>Portal and Hepatic Vein Embolization</arm_group_label>
    <other_name>Liver venous deprivation (LVD)</other_name>
    <other_name>Double embolization</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with primarily unresectable/potentially resectable CRLM after conversion
             chemotherapy with a FLR &lt;30% in normal livers, or 40% in livers chemotherapy damaged
             livers.

          -  18 years and older

          -  Patients up to ECOG 3 (not more than 50% bedbound)

          -  Patients with non-resected primary colorectal cancer (CRC) may be included if and only
             if there is an intent to remove the CRC after the liver treatment (liver first
             approach)

          -  Staging CT chest and (if symptomatic) CT/MRI excludes unresectable extrahepatic
             disease, while metastatic disease that may be cured in the future, is included.

          -  Patients with resectable lung metastases or lung metastases that and be ablated can be
             included only after statement about resectability/ablatability by tumor board

          -  Patients have to be to understand the trial and provide informed consent.

        Exclusion Criteria:

          -  Patients with extrahepatic disease other than lung metastases

          -  Patients with metastatic disease to the lung that cannot be ablated or resected will
             be excluded

          -  Patients with intrahepatic Cholangiocarcinoma (IHCC)

          -  Patients with Perihilar Cholangiocarcinoma (PHCC)

          -  Patients with Hepatocellular Carcinoma (HCC)

          -  Pregnant or lactating women will not be eligible

          -  Potential to get pregnant has to be excluded (obligatory contraception etc.)

          -  Progression by modified RECIST criteria on cross-sectional imaging after conversion
             chemotherapy is an exclusion criterion. Complete response in cross-sectional imaging
             after conversion chemotherapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald M van Dam, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Erik Schadde, MD FACS FEBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kantonsspital Winterthur/ Rush University Medical Center, Chicago</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc AH Bemelmans, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christiaan van der Leij, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christoph A Binkert, Prof.Dr.Med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cantonal Hospital Winterthur</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Remon Korenblik, MD</last_name>
    <phone>+31 637297507</phone>
    <email>remon.korenblik@mumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ronald M. van Dam, MD, PhD</last_name>
    <email>r.van.dam@mumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Social Medical Center, South</name>
      <address>
        <city>Vienna</city>
        <zip>1100</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Gruenberger, MD</last_name>
      <email>tgruenberger@icloud.com</email>
    </contact>
    <contact_backup>
      <last_name>Tanja Friz, BSc</last_name>
      <email>tanjafritz2@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas Gruenberger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tony Padickakudy</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tanja Fritz</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ivan Baclija</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS San Raffaele Hospital</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luca Aldrighetti, Prof</last_name>
      <email>aldrighetti.luca@hsr.it</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie Steidler</last_name>
      <email>steidler.stephanie@hsr.it</email>
    </contact_backup>
    <investigator>
      <last_name>Luca Aldrighetti, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesco De Cobelli, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesca Ratti, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simone Gusmini, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Salvatore Lamarca, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephanie Steidler</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center+</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Remon Korenblik, MD</last_name>
      <phone>+31637297507</phone>
      <email>remon.korenblik@mumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Ronald M van Dam, MD, PhD</last_name>
      <email>r.van.dam@mumc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Ronald M van Dam, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc H.A. Bemelmans, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christiaan van der Leij, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Remon Korenblik, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bram Olij, BCs</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amsterdam Medical Centers, Location VUmc</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martijn R Meijerink, MD PhD</last_name>
      <email>mr.meijerink@amsterdamumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Evelien Schouten</last_name>
      <email>e.schouten@amsterdamumc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Martijn R Meijerink, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Geert Kazemier, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jan de Vries, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Evelien Schouten</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marieke T de Boer, MD PhD</last_name>
      <email>m.t.de.boer@umcg.nl</email>
    </contact>
    <contact_backup>
      <last_name>Jan T Bottema</last_name>
      <email>j.t.bottema@umcg.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Marieke T de Boer, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Koert P de Jong</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Reinhoud PH Bokkers</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jan T Bottema</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leanne van der Plas - Kemper</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <zip>581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Per Sandström, Prof.</last_name>
      <email>per.sandstrom@liu.se</email>
    </contact>
    <contact_backup>
      <last_name>Bergthor Bjornsson, MD</last_name>
      <email>bergthor.bjornsson@liu.se</email>
    </contact_backup>
    <investigator>
      <last_name>Per Sandström, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bergthor Bjornsson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Margareta Ahle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Lindhoff Larsson</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ernesto Sparrelid, MD</last_name>
      <email>ernesto.sparrelid@ki.se</email>
    </contact>
    <contact_backup>
      <last_name>Martin Delle, MD</last_name>
      <email>martin.delle@sll.se</email>
    </contact_backup>
    <investigator>
      <last_name>Ernesto Sparrelid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Delle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Claraspital &amp; Clarunis University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <state>Basel-Stadt</state>
        <zip>CH-4058</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Otto Kollmar, Prof.</last_name>
      <email>otto.kollmar@clarunis.ch</email>
    </contact>
    <contact_backup>
      <last_name>Bettina Woelnerhanssen</last_name>
      <email>Bettina.Woelnerhanssen@claraspital.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Otto Kollmar, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Hoffman, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gabriel Hess, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bettina Woelnershanssen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur (KSW)</name>
      <address>
        <city>Winterthur</city>
        <zip>8401</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erik Schadde, MD</last_name>
      <email>erik.schadde@icloud.com</email>
    </contact>
    <contact_backup>
      <last_name>Sabine Kern</last_name>
      <email>Sabine.Kern@usz.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Chistoph A Binkert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erik Schadde, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Sweden</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 7, 2020</study_first_submitted>
  <study_first_submitted_qc>February 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Future Liver Remnant</keyword>
  <keyword>Portal and Hepatic Vein Embolization</keyword>
  <keyword>Colorectal Liver Metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

